Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Статины в практике терапевта
Статины в практике терапевта
Сусеков А.В. Статины в практике терапевта. Consilium Medicum. 2024;26(10):641–648.
DOI: 10.26442/20751753.2024.10.202995
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
DOI: 10.26442/20751753.2024.10.202995
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статины как основа лечения и профилактики атеросклероза и его осложнений применяются в клинической практике более 40 лет. Результаты наблюдательных исследований свидетельствуют о том, что, несмотря на большую доказательную базу, статины в России по-прежнему назначают в низких дозах, максимум на 6 мес, что ведет к низкому проценту достижения целевых уровней холестерина липопротеинов низкой плотности и, соответственно, к высокому остаточному риску сердечно-сосудистых осложнений. В этой публикации представлен литературный обзор и аналитика основных принципов терапии статинами в первичной профилактике, интенсивной липидснижающей терапии у больных очень высокого сердечно-сосудистого риска, а также ключевые обновления безопасности снижения холестерина по различным органам и системам (печени, почкам, мышцам, нервной системе), углеводному обмену. В статье также представлен краткий обзор новых международных рекомендаций по оптимизации диагностики и лечения дислипидемий, что может быть полезно в повседневной практике терапевта.
Ключевые слова: первичная профилактика, дислипидемия, статины, эзетимиб, холестерин липопротеинов низкой плотности, рекомендации, сердечно-сосудистый риск, безопасность, сахарный диабет, миопатии, гиперферментемия, деменция, хроническая почечная недостаточность
Keywords: primary prevention, dyslipidemia, statins, ezetimibe, low-density lipoprotein cholesterol, recommendations, cardiovascular risk, safety, diabetes mellitus, myopathies, hyperenzymemia, dementia, chronic renal failure
Ключевые слова: первичная профилактика, дислипидемия, статины, эзетимиб, холестерин липопротеинов низкой плотности, рекомендации, сердечно-сосудистый риск, безопасность, сахарный диабет, миопатии, гиперферментемия, деменция, хроническая почечная недостаточность
________________________________________________
Keywords: primary prevention, dyslipidemia, statins, ezetimibe, low-density lipoprotein cholesterol, recommendations, cardiovascular risk, safety, diabetes mellitus, myopathies, hyperenzymemia, dementia, chronic renal failure
Полный текст
Список литературы
1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-350. DOI:10.1016/j.jacc.2018.11.003
2. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG). ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. DOI:10.1016/j.atherosclerosis.2019.08.014
3. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab484
4. Нарушения липидного обмена. Клинические рекомендации. 2023. Режим доступа: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Ссылка активна на 23.06.2024 [Narusheniia lipidnogo obmena. Klinicheskie rekomendatsii. 2023. Available at: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Accessed: 23.06.2024 (in Russian)].
5. Острый коронарный синдром без подъема сегмента ST кардиограммы. Клинические рекомендации. 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Ссылка активна на 23.06.2024 [Ostryi koronarnyi sindrom bez pod"ema segmenta ST kardiogrammy. Klinicheskie rekomendatsii. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Accessed: 23.06.2024 (in Russian)].
6. Бойцов С.А., Погосова Н.В., Аншелес А.А., и др. Кардиоваскулярная профилактика. Клинические рекомендации. Российский кардиологический журнал. 2023;28(5):5452 [Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452 (in Russian)]. DOI:10.15829/1560-4071-2023-5452
7. Котовская Ю.В., Ткачева О.Н., Сергиенко И.В. Липидснижающая терапия для первичной профилактики у пациентов 75 лет и старше. Консенсус экспертов Российской ассоциации геронтологов и гериатров, Национального общества по изучению атеросклероза, Российского кардиологического общества, Ассоциации клинических фармакологов. Кардиология. 2020;60(6):119-32 [Kotovskaya YV, Tkacheva ON, Sergienko IV. Lipid-lowering therapy for primary cardiovascular prevention in older adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119-32 (in Russian)]. DOI:10.18087/cardio.2020.6.n1037
8. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97. DOI:10.1056/NEJMoa1410489
9. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664
10. Schwartz GG, Steg GP, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-107. DOI:10.1056/NEJMoa1801174
11. Ray KK, Ference BA, Séverin T, et al. Word Heart Federation Cholesterol Roadmap 2022. Global Heart. 2022;17(1):75. DOI:10.5334/gh.1154
12. Romanelli RJ, Ito MK, Karalis DG, et al. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016. J Clin Lipidol. 2020;14(3):305-14. DOI:10.1016/j.jacl.2020.03.006
13. Navar AN, Kolkailah A, Gillard KK, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: A retrospective cohort study of 322153 patients. Circ Cardiovasc Qual Outcomes. 2023;16:e009787. DOI:10.1161/CIRCOUTCOMES.122.00978
14. Barrios V, Soronen L, Carter A et al. Lipid management across Europe in the real-world setting: A rapid evidence review. Cardiovascular Medicine. Curr Med Res Opin. 2021;37(12):2049-59. DOI:10.1080/03007995.2021.1973396
15. Ray K, Haq I, Manu MC; SANTORINI Study Investigators, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. DOI:10.1016/j.lanepe.2023.100624
16. Pinto L, Farghaly M, Nunna S, et al. Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates. PLoS One. 2022;17(9):e0268709. DOI:10.1371/journal.pone.0268709
17. Guo T, Chu C, Wang C, et al. Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: A sub analysis of Dyslipidemia International Study II – China. BMC Cardiovasc Disord. 2023;23(1):337. DOI:10.1186/s12872-023-03312-w
18. Сусеков А.В. Обоснование повышения доз статинов в повседневной практике. Кардиология. 2024;64(8):79-88 [Susekov AV. Rationale for increasing doses of statins in everyday clinical practice. Kardiologiia. 2024;64(8):79-88 (in Russian)]. DOI:10.18087/cardio.2024.8.n2709
19. Драпкина О.М., Имаева А.Э., Куценко В.А., и др. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3791 [Drapkina OM, Imaeva AE, Kutsenko VA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791 (in Russian)]. DOI:10.15829/1728-8800-2023-3791
20. Papadaki A, Nolen-Doerr E, Mantzoros CS. The effect of the mediterranean diet on metabolic health: A systematic review and meta-analysis of controlled trials in adults. Nutrients. 2020;12(11):3342. DOI:10.3390/nu12113342
21. Сусеков А.В. Актуальные вопросы современной гиполипидемической терапии. Consilium Medicum. 2022;24(1):20-7 [Susekov AV. Topical issues concerning modern lipid-lowering therapy. Consilium Medicum. 2022;24(1):20-7 (in Russian)]. DOI:10.26442/20751753.2022.1.201484
22. Сусеков А.В. Современные алгоритмы терапии статинами. Российский кардиологический журнал. 2023;28(10):5594 [Susekov VA. Modern algorithms for statin therapy. Russian Journal of Cardiology. 2023;28(10):5594 (in Russian)]. DOI:10.15829/1560-4071-2023-5594
23. Brus S. Clinical evidence of the efficacy of Krka’s rosuvastatin in the treatment of hyperlipidemia with focus on additional doses. Krka Med Farm. 2014;26(38):62-71. DOI:10.15836/ccar.2014.320
24. European patent office. Munich. EP 2 387 566 B1. Available at: https://data.epo.org. Accessed: 17.10.2014.
25. Сергиенко И.В., Аншелес А.А., Бойцов С.А. Факторы риска, показатели липидного профиля и гиполипидемическая терапия у пациентов различных категорий сердечно-сосудистого риска: данные регистра Атеростоп. Атеросклероз и дислипидемии. 2023;2(51):43-53 [Sergienko IV, Ansheles AA, Boytsov SA. Risk factors, lipid profile indicators and hypolipidemic therapy in patients of various categories of cardiovascular risk: the results of the Aterostop registry. Ateroskleroz i Dislipidemii = The Journal of Atherosclerosis and Dyslipidemias. 2023;2(51):43-53 (in Russian)]. DOI:10.34687/2219-8202.JAD.2023.02.0005
26. Рекомендации для врачей по ведению пациентов с дислипидемией и атеросклерозом. Под ред. А.В. Сусекова. М.: Ре Медиа, 2022 [Rekomendatsii dlia vrachei po vedeniiu patsientov s dislipidemiei i aterosklerozom. Pod red. AV Susekova. Moscow: Re Media, 2022 (in Russian)].
27. Ramaswami U, Humphries SE, Priestley-Barnham L, еt al. Current management of children and young people with heterozygous familial hypercholesterolaemia – HEART UK statement of care. Atherosclerosis. 2019;290:1-8. DOI:10.1016/j.atherosclerosis.2019.09.005
28. Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ. 2003;326:1407-8. Vasc Med. 2003;8(4):289-90. DOI:10.1191/1358863x03vm518xx
29. Orringer CE, Blaha MJ, Blankstein R, еt al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33-60. DOI:10.1016/j.jacl.2020.12.005
30. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement EAS consensus aortic stenosis. Eur Heart J. 2022;43(39):3925-46. DOI:10.1093/eurheartj/ehac361
31. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-93. DOI:10.1016/j.jacc.2021.06.011
32. Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): An update on a marker of residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94-102. DOI:10.1016/j.amjcard.2020.03.043
33. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. DOI:10.1111/joim.13016
34. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis. 2018;275:265-72. DOI:10.1016/j.atherosclerosis.2018.06.814
35. Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, et al. Women, lipids, and atherosclerotic cardiovascular disease: A call to action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157-73. DOI:10.1093/eurheartj/ehad472
36. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-314. DOI:10.1016/j.kint.2023.10.018
37. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events a scientific statement from the AHA. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-81. DOI:10.1161/ATV.0000000000000073
38. Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526-39. DOI:10.1093/eurheartj/ehy182
39. Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complains. J Am Coll Cardiol. 2017;70(10):290-301. DOI:10.1016/j.jacc.2017.07.752
40. Vell MS, Loomba R, Krishman A. Association of statin use with risk of liver disease, hepatocellular carcinoma and liver-related mortality. JAMA Network Open. 2023;6(6):e2320222. DOI:10.1001/jamanetworkopen.2023.20222
41. Warden BA, Guyton JR, Kovaks AS, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19-39. DOI:10.1016/j.jacl.2022.09.001
42. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al Aggressive LDL-C lowering and the brain: Impact on risk for dementia and hemorrhagic stroke: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43:e404-42. DOI:10.1161/ATV.0000000000000164
43. Sattar N. Statins and diabetes: What are the connections? Best Pract Res Clin Endocrinol Metab. 2023;37(3):101749. DOI:10.1016/j.beem.2023.101749
44. Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S47-57. DOI:10.1016/j.jacl.2014.02.011
45. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-34. DOI:10.1023/a:1005661516165
46. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412-22. DOI:10.1055/s-0029-1240010
47. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374-80. DOI:10.1016/j.jhep.2011.07.023
48. Kajinami K, Tsukamoto K, Koba S, et al. Statin Intolerance Clinical Guide 2018. J Atherosclerosis Thromb. 2020;27(4):375-96. DOI:10.5551/jat.50948
49. Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc Drugs Ther. 2021;35(4):841-52. DOI:10.1007/s10557-020-07139-x
50. Воевода М.И., Гуревич В.С., Ежов М.В., Сергиенко И.В. Инклисиран – новая эра в гиполипидемической терапии. Кардиология. 2022;62(6):57-62 [Voevoda MI, Gurevich VS, Ezhov MV, Sergienko IV. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia. 2022;62(6):57-62 (in Russian)]. DOI:10.18087/cardio.2022.6.n2115
51. Rosenson RS, Baker SK, Jacobson TA, et al.; The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S58-71. DOI:10.1016/j.jacl.2014.03.004
52. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-59. PMID:8245716
53. Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S5-16. DOI:10.1016/j.jacl.2014.02.013
54. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. 2012;5(6):746-55. DOI:10.1242/dmm.01012
55. de Boer AG, Gaillard PJ. Blood-brain barrier dysfunction and recovery. J Neural Transm (Vienna). 2006;113(4):455-62. DOI:10.1007/s00702-005-0375-4
56. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22). N Engl J Med. 2004;350(15):1495-504. DOI:10.1056/NEJMoa040583
57. Nicholls S, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87. DOI:10.1056/NEJMoa1110874
58. Nissen S, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13):1556-65. DOI:10.1001/jama.295.13.jpc60002
59. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-80. DOI:10.1016/j.amjcard.2006.10.022
60. Olmastroni E, Molari G, DeBeni N, et al. Statin use and risk of dementia or Alzheimer's disease: A systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804-14. DOI:10.1093/eurjpc/zwab208
61. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-58. DOI:10.1002/pds.3381
62. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. М., 2023 [Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. II Dedova, MV Shestakovoi, AIu Maiorova. 11-i vyp. Moscow, 2023 (in Russian)]. DOI:10.14341/DM13042
63. Цыганкова О.В., Евдокимова Н.Е., Байрамова С.С., Сусеков А.В. Статин-ассоциированный рабдомиолиз у женщины 60 лет с декомпенсированным сахарным диабетом 2 типа. Российский кардиологический журнал. 2021;26(11):44171 [Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: A case report. Russian Journal of Cardiology. 2021;26(11):4471 (in Russian)]. DOI:10.15829/1560-4071-2021-4471
64. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. DOI:10.1093/eurheartj/ehad192
65. Byrne RA, Rosselo X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. DOI:10.1093/eurheartj/ehad191
66. Davidson MH. Rosuvastatin safety: lessons from the FDA review and postapproval surveillance. Expert Opin Drug Safety. 2004;3(6):547-57. DOI:10.1517/14740338.3.6.547
67. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet. 2011;377(9784):2181-92. DOI:10.1016/S0140-6736(11)60739-3
68. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-94.e10. DOI:10.1016/j.ahj.2010.08.012
69. Sabouret P, Puymirat E, Kownator S, et al. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Panminerva Med. 2023;65(2):244-9. DOI:10.23736/S0031-0808.22.04777-2
70. Li JJ, Zhao SP, Zhao D, et al. 2023 China Guidelines for Lipid Management. J Geriatr Cardiology. 2023;20(9):621-63. DOI:10.26599/1671-5411.2023.09.008
71. Araujo F, Caldera D, Aguiar C, et al. Polypill use for the prevention of cardiovascular disease: A position paper. Rev Port Cardiol. 2023;42(10):861-72. DOI:10.1016/j.repc.2023.02.011
72. Puri R, Bansal M, Mehta V, et al. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV. J Clin Lipidology. 2024;18(3):e315-73. DOI:10.1016/j.jacl.2024.01.006
73. Bangalore S, Fayyad R, Kastelein JJ, et al. 2013 Cholesterol Guidelines Revisited: Percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis? Am J Med. 2016;129(4):384-91. DOI:10.1016/j.amjmed.2015.10.024
74. Метельская В.А., Шальнова С.А., Деев А.Д., и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016;1:15-23 [Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Russian Journal of Preventive Medicine. 2016;19(1):15-23 (in Russian)]. DOI:10.17116/profmed201619115-23
75. Мешков А.Н., Ершова А.И., Деев А.Д., и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012–2014 гг. Кардиоваскулярная терапия и профилактика. 2017;16(4):62-7 [Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: Results of the Esse-RF Study for the years 2012–2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7 (in Russian)]. DOI:10.15829/1728-8800-2017-4-62-67
76. Игонина Н.А., Журавлева Е.А., Кондрашева Е.А., и др. Анализ данных массового исследования холестерина у населения (к вопросу о референсных значениях холестерина). Клиническая лабораторная диагностика. 2013;1:11-7 [Igonina NA, Juravleva EA, Kondrasheva EA, et al. The analysis of data of large study of cholesterol level in population: On the issue of reference values of cholesterol). Russian Clinical Laboratory Diagnostics. 2013;1:11-7 (in Russian)].
77. Бойцов С.А., Шахнович Р.М., Терещенко С.Н., и др. Распространенность гиперлипидемии и особенности липидснижающей терапии у пациентов с инфарктом миокарда по данным Российского регистра острого инфаркта миокарда РЕГИОН-ИМ. Кардиология. 2022;62(7):12-22 [Boytsov SA, Shakhnovich RM, Tereschenko SN, et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12-22 (in Russian)]. DOI:10.18087/cardio.2022.7.n2051
78. Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С., и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I. Рациональная фармакотерапия в кардиологии. 2015;11(3):253-60 [Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I. Ration Pharmacother Cardiol. 2015;11(3):253-60 (in Russian)].
79. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;11(4):70-8 [Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8 (in Russian)].
2. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG). ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. DOI:10.1016/j.atherosclerosis.2019.08.014
3. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab484
4. Narusheniia lipidnogo obmena. Klinicheskie rekomendatsii. 2023. Available at: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Accessed: 23.06.2024 (in Russian).
5. Ostryi koronarnyi sindrom bez pod"ema segmenta ST kardiogrammy. Klinicheskie rekomendatsii. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Accessed: 23.06.2024 (in Russian).
6. Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452 (in Russian). DOI:10.15829/1560-4071-2023-5452
7. Kotovskaya YV, Tkacheva ON, Sergienko IV. Lipid-lowering therapy for primary cardiovascular prevention in older adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119-32 (in Russian). DOI:10.18087/cardio.2020.6.n1037
8. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97. DOI:10.1056/NEJMoa1410489
9. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664
10. Schwartz GG, Steg GP, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-107. DOI:10.1056/NEJMoa1801174
11. Ray KK, Ference BA, Séverin T, et al. Word Heart Federation Cholesterol Roadmap 2022. Global Heart. 2022;17(1):75. DOI:10.5334/gh.1154
12. Romanelli RJ, Ito MK, Karalis DG, et al. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016. J Clin Lipidol. 2020;14(3):305-14. DOI:10.1016/j.jacl.2020.03.006
13. Navar AN, Kolkailah A, Gillard KK, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: A retrospective cohort study of 322153 patients. Circ Cardiovasc Qual Outcomes. 2023;16:e009787. DOI:10.1161/CIRCOUTCOMES.122.00978
14. Barrios V, Soronen L, Carter A et al. Lipid management across Europe in the real-world setting: A rapid evidence review. Cardiovascular Medicine. Curr Med Res Opin. 2021;37(12):2049-59. DOI:10.1080/03007995.2021.1973396
15. Ray K, Haq I, Manu MC; SANTORINI Study Investigators, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. DOI:10.1016/j.lanepe.2023.100624
16. Pinto L, Farghaly M, Nunna S, et al. Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates. PLoS One. 2022;17(9):e0268709. DOI:10.1371/journal.pone.0268709
17. Guo T, Chu C, Wang C, et al. Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: A sub analysis of Dyslipidemia International Study II – China. BMC Cardiovasc Disord. 2023;23(1):337. DOI:10.1186/s12872-023-03312-w
18. Susekov AV. Rationale for increasing doses of statins in everyday clinical practice. Kardiologiia. 2024;64(8):79-88 (in Russian). DOI:10.18087/cardio.2024.8.n2709
19. Drapkina OM, Imaeva AE, Kutsenko VA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791 (in Russian). DOI:10.15829/1728-8800-2023-3791
20. Papadaki A, Nolen-Doerr E, Mantzoros CS. The effect of the mediterranean diet on metabolic health: A systematic review and meta-analysis of controlled trials in adults. Nutrients. 2020;12(11):3342. DOI:10.3390/nu12113342
21. Susekov AV. Topical issues concerning modern lipid-lowering therapy. Consilium Medicum. 2022;24(1):20-7 (in Russian). DOI:10.26442/20751753.2022.1.201484
22. Susekov VA. Modern algorithms for statin therapy. Russian Journal of Cardiology. 2023;28(10):5594 (in Russian). DOI:10.15829/1560-4071-2023-5594
23. Brus S. Clinical evidence of the efficacy of Krka’s rosuvastatin in the treatment of hyperlipidemia with focus on additional doses. Krka Med Farm. 2014;26(38):62-71. DOI:10.15836/ccar.2014.320
24. European patent office. Munich. EP 2 387 566 B1. Available at: https://data.epo.org. Accessed: 17.10.2014.
25. Sergienko IV, Ansheles AA, Boytsov SA. Risk factors, lipid profile indicators and hypolipidemic therapy in patients of various categories of cardiovascular risk: the results of the Aterostop registry. Ateroskleroz i Dislipidemii = The Journal of Atherosclerosis and Dyslipidemias. 2023;2(51):43-53 (in Russian). DOI:10.34687/2219-8202.JAD.2023.02.0005
26. Rekomendatsii dlia vrachei po vedeniiu patsientov s dislipidemiei i aterosklerozom. Pod red. AV Susekova. Moscow: Re Media, 2022 (in Russian).
27. Ramaswami U, Humphries SE, Priestley-Barnham L, еt al. Current management of children and young people with heterozygous familial hypercholesterolaemia – HEART UK statement of care. Atherosclerosis. 2019;290:1-8. DOI:10.1016/j.atherosclerosis.2019.09.005
28. Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ. 2003;326:1407-8. Vasc Med. 2003;8(4):289-90. DOI:10.1191/1358863x03vm518xx
29. Orringer CE, Blaha MJ, Blankstein R, еt al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33-60. DOI:10.1016/j.jacl.2020.12.005
30. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement EAS consensus aortic stenosis. Eur Heart J. 2022;43(39):3925-46. DOI:10.1093/eurheartj/ehac361
31. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-93. DOI:10.1016/j.jacc.2021.06.011
32. Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): An update on a marker of residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94-102. DOI:10.1016/j.amjcard.2020.03.043
33. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. DOI:10.1111/joim.13016
34. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis. 2018;275:265-72. DOI:10.1016/j.atherosclerosis.2018.06.814
35. Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, et al. Women, lipids, and atherosclerotic cardiovascular disease: A call to action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157-73. DOI:10.1093/eurheartj/ehad472
36. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-314. DOI:10.1016/j.kint.2023.10.018
37. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events a scientific statement from the AHA. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-81. DOI:10.1161/ATV.0000000000000073
38. Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526-39. DOI:10.1093/eurheartj/ehy182
39. Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complains. J Am Coll Cardiol. 2017;70(10):290-301. DOI:10.1016/j.jacc.2017.07.752
40. Vell MS, Loomba R, Krishman A. Association of statin use with risk of liver disease, hepatocellular carcinoma and liver-related mortality. JAMA Network Open. 2023;6(6):e2320222. DOI:10.1001/jamanetworkopen.2023.20222
41. Warden BA, Guyton JR, Kovaks AS, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19-39. DOI:10.1016/j.jacl.2022.09.001
42. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al Aggressive LDL-C lowering and the brain: Impact on risk for dementia and hemorrhagic stroke: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43:e404-42. DOI:10.1161/ATV.0000000000000164
43. Sattar N. Statins and diabetes: What are the connections? Best Pract Res Clin Endocrinol Metab. 2023;37(3):101749. DOI:10.1016/j.beem.2023.101749
44. Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S47-57. DOI:10.1016/j.jacl.2014.02.011
45. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-34. DOI:10.1023/a:1005661516165
46. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412-22. DOI:10.1055/s-0029-1240010
47. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374-80. DOI:10.1016/j.jhep.2011.07.023
48. Kajinami K, Tsukamoto K, Koba S, et al. Statin Intolerance Clinical Guide 2018. J Atherosclerosis Thromb. 2020;27(4):375-96. DOI:10.5551/jat.50948
49. Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc Drugs Ther. 2021;35(4):841-52. DOI:10.1007/s10557-020-07139-x
50. Voevoda MI, Gurevich VS, Ezhov MV, Sergienko IV. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia. 2022;62(6):57-62 (in Russian). DOI:10.18087/cardio.2022.6.n2115
51. Rosenson RS, Baker SK, Jacobson TA, et al.; The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S58-71. DOI:10.1016/j.jacl.2014.03.004
52. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-59. PMID:8245716
53. Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S5-16. DOI:10.1016/j.jacl.2014.02.013
54. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. 2012;5(6):746-55. DOI:10.1242/dmm.01012
55. de Boer AG, Gaillard PJ. Blood-brain barrier dysfunction and recovery. J Neural Transm (Vienna). 2006;113(4):455-62. DOI:10.1007/s00702-005-0375-4
56. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22). N Engl J Med. 2004;350(15):1495-504. DOI:10.1056/NEJMoa040583
57. Nicholls S, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87. DOI:10.1056/NEJMoa1110874
58. Nissen S, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13):1556-65. DOI:10.1001/jama.295.13.jpc60002
59. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-80. DOI:10.1016/j.amjcard.2006.10.022
60. Olmastroni E, Molari G, DeBeni N, et al. Statin use and risk of dementia or Alzheimer's disease: A systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804-14. DOI:10.1093/eurjpc/zwab208
61. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-58. DOI:10.1002/pds.3381
62. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. II Dedova, MV Shestakovoi, AIu Maiorova. 11-i vyp. Moscow, 2023 (in Russian). DOI:10.14341/DM13042
63. Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: A case report. Russian Journal of Cardiology. 2021;26(11):4471 (in Russian). DOI:10.15829/1560-4071-2021-4471
64. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. DOI:10.1093/eurheartj/ehad192
65. Byrne RA, Rosselo X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. DOI:10.1093/eurheartj/ehad191
66. Davidson MH. Rosuvastatin safety: lessons from the FDA review and postapproval surveillance. Expert Opin Drug Safety. 2004;3(6):547-57. DOI:10.1517/14740338.3.6.547
67. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet. 2011;377(9784):2181-92. DOI:10.1016/S0140-6736(11)60739-3
68. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-94.e10. DOI:10.1016/j.ahj.2010.08.012
69. Sabouret P, Puymirat E, Kownator S, et al. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Panminerva Med. 2023;65(2):244-9. DOI:10.23736/S0031-0808.22.04777-2
70. Li JJ, Zhao SP, Zhao D, et al. 2023 China Guidelines for Lipid Management. J Geriatr Cardiology. 2023;20(9):621-63. DOI:10.26599/1671-5411.2023.09.008
71. Araujo F, Caldera D, Aguiar C, et al. Polypill use for the prevention of cardiovascular disease: A position paper. Rev Port Cardiol. 2023;42(10):861-72. DOI:10.1016/j.repc.2023.02.011
72. Puri R, Bansal M, Mehta V, et al. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV. J Clin Lipidology. 2024;18(3):e315-73. DOI:10.1016/j.jacl.2024.01.006
73. Bangalore S, Fayyad R, Kastelein JJ, et al. 2013 Cholesterol Guidelines Revisited: Percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis? Am J Med. 2016;129(4):384-91. DOI:10.1016/j.amjmed.2015.10.024
74. Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Russian Journal of Preventive Medicine. 2016;19(1):15-23 (in Russian). DOI:10.17116/profmed201619115-23
75. Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: Results of the Esse-RF Study for the years 2012–2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7 (in Russian). DOI:10.15829/1728-8800-2017-4-62-67
76. Igonina NA, Juravleva EA, Kondrasheva EA, et al. The analysis of data of large study of cholesterol level in population: On the issue of reference values of cholesterol). Russian Clinical Laboratory Diagnostics. 2013;1:11-7 (in Russian).
77. Boytsov SA, Shakhnovich RM, Tereschenko SN, et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12-22 (in Russian). DOI:10.18087/cardio.2022.7.n2051
78. Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I. Ration Pharmacother Cardiol. 2015;11(3):253-60 (in Russian).
79. Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8 (in Russian).
2. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG). ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. DOI:10.1016/j.atherosclerosis.2019.08.014
3. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab484
4. Нарушения липидного обмена. Клинические рекомендации. 2023. Режим доступа: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Ссылка активна на 23.06.2024 [Narusheniia lipidnogo obmena. Klinicheskie rekomendatsii. 2023. Available at: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Accessed: 23.06.2024 (in Russian)].
5. Острый коронарный синдром без подъема сегмента ST кардиограммы. Клинические рекомендации. 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Ссылка активна на 23.06.2024 [Ostryi koronarnyi sindrom bez pod"ema segmenta ST kardiogrammy. Klinicheskie rekomendatsii. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Accessed: 23.06.2024 (in Russian)].
6. Бойцов С.А., Погосова Н.В., Аншелес А.А., и др. Кардиоваскулярная профилактика. Клинические рекомендации. Российский кардиологический журнал. 2023;28(5):5452 [Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452 (in Russian)]. DOI:10.15829/1560-4071-2023-5452
7. Котовская Ю.В., Ткачева О.Н., Сергиенко И.В. Липидснижающая терапия для первичной профилактики у пациентов 75 лет и старше. Консенсус экспертов Российской ассоциации геронтологов и гериатров, Национального общества по изучению атеросклероза, Российского кардиологического общества, Ассоциации клинических фармакологов. Кардиология. 2020;60(6):119-32 [Kotovskaya YV, Tkacheva ON, Sergienko IV. Lipid-lowering therapy for primary cardiovascular prevention in older adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119-32 (in Russian)]. DOI:10.18087/cardio.2020.6.n1037
8. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97. DOI:10.1056/NEJMoa1410489
9. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664
10. Schwartz GG, Steg GP, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-107. DOI:10.1056/NEJMoa1801174
11. Ray KK, Ference BA, Séverin T, et al. Word Heart Federation Cholesterol Roadmap 2022. Global Heart. 2022;17(1):75. DOI:10.5334/gh.1154
12. Romanelli RJ, Ito MK, Karalis DG, et al. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016. J Clin Lipidol. 2020;14(3):305-14. DOI:10.1016/j.jacl.2020.03.006
13. Navar AN, Kolkailah A, Gillard KK, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: A retrospective cohort study of 322153 patients. Circ Cardiovasc Qual Outcomes. 2023;16:e009787. DOI:10.1161/CIRCOUTCOMES.122.00978
14. Barrios V, Soronen L, Carter A et al. Lipid management across Europe in the real-world setting: A rapid evidence review. Cardiovascular Medicine. Curr Med Res Opin. 2021;37(12):2049-59. DOI:10.1080/03007995.2021.1973396
15. Ray K, Haq I, Manu MC; SANTORINI Study Investigators, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. DOI:10.1016/j.lanepe.2023.100624
16. Pinto L, Farghaly M, Nunna S, et al. Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates. PLoS One. 2022;17(9):e0268709. DOI:10.1371/journal.pone.0268709
17. Guo T, Chu C, Wang C, et al. Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: A sub analysis of Dyslipidemia International Study II – China. BMC Cardiovasc Disord. 2023;23(1):337. DOI:10.1186/s12872-023-03312-w
18. Сусеков А.В. Обоснование повышения доз статинов в повседневной практике. Кардиология. 2024;64(8):79-88 [Susekov AV. Rationale for increasing doses of statins in everyday clinical practice. Kardiologiia. 2024;64(8):79-88 (in Russian)]. DOI:10.18087/cardio.2024.8.n2709
19. Драпкина О.М., Имаева А.Э., Куценко В.А., и др. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3791 [Drapkina OM, Imaeva AE, Kutsenko VA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791 (in Russian)]. DOI:10.15829/1728-8800-2023-3791
20. Papadaki A, Nolen-Doerr E, Mantzoros CS. The effect of the mediterranean diet on metabolic health: A systematic review and meta-analysis of controlled trials in adults. Nutrients. 2020;12(11):3342. DOI:10.3390/nu12113342
21. Сусеков А.В. Актуальные вопросы современной гиполипидемической терапии. Consilium Medicum. 2022;24(1):20-7 [Susekov AV. Topical issues concerning modern lipid-lowering therapy. Consilium Medicum. 2022;24(1):20-7 (in Russian)]. DOI:10.26442/20751753.2022.1.201484
22. Сусеков А.В. Современные алгоритмы терапии статинами. Российский кардиологический журнал. 2023;28(10):5594 [Susekov VA. Modern algorithms for statin therapy. Russian Journal of Cardiology. 2023;28(10):5594 (in Russian)]. DOI:10.15829/1560-4071-2023-5594
23. Brus S. Clinical evidence of the efficacy of Krka’s rosuvastatin in the treatment of hyperlipidemia with focus on additional doses. Krka Med Farm. 2014;26(38):62-71. DOI:10.15836/ccar.2014.320
24. European patent office. Munich. EP 2 387 566 B1. Available at: https://data.epo.org. Accessed: 17.10.2014.
25. Сергиенко И.В., Аншелес А.А., Бойцов С.А. Факторы риска, показатели липидного профиля и гиполипидемическая терапия у пациентов различных категорий сердечно-сосудистого риска: данные регистра Атеростоп. Атеросклероз и дислипидемии. 2023;2(51):43-53 [Sergienko IV, Ansheles AA, Boytsov SA. Risk factors, lipid profile indicators and hypolipidemic therapy in patients of various categories of cardiovascular risk: the results of the Aterostop registry. Ateroskleroz i Dislipidemii = The Journal of Atherosclerosis and Dyslipidemias. 2023;2(51):43-53 (in Russian)]. DOI:10.34687/2219-8202.JAD.2023.02.0005
26. Рекомендации для врачей по ведению пациентов с дислипидемией и атеросклерозом. Под ред. А.В. Сусекова. М.: Ре Медиа, 2022 [Rekomendatsii dlia vrachei po vedeniiu patsientov s dislipidemiei i aterosklerozom. Pod red. AV Susekova. Moscow: Re Media, 2022 (in Russian)].
27. Ramaswami U, Humphries SE, Priestley-Barnham L, еt al. Current management of children and young people with heterozygous familial hypercholesterolaemia – HEART UK statement of care. Atherosclerosis. 2019;290:1-8. DOI:10.1016/j.atherosclerosis.2019.09.005
28. Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ. 2003;326:1407-8. Vasc Med. 2003;8(4):289-90. DOI:10.1191/1358863x03vm518xx
29. Orringer CE, Blaha MJ, Blankstein R, еt al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33-60. DOI:10.1016/j.jacl.2020.12.005
30. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement EAS consensus aortic stenosis. Eur Heart J. 2022;43(39):3925-46. DOI:10.1093/eurheartj/ehac361
31. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-93. DOI:10.1016/j.jacc.2021.06.011
32. Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): An update on a marker of residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94-102. DOI:10.1016/j.amjcard.2020.03.043
33. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. DOI:10.1111/joim.13016
34. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis. 2018;275:265-72. DOI:10.1016/j.atherosclerosis.2018.06.814
35. Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, et al. Women, lipids, and atherosclerotic cardiovascular disease: A call to action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157-73. DOI:10.1093/eurheartj/ehad472
36. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-314. DOI:10.1016/j.kint.2023.10.018
37. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events a scientific statement from the AHA. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-81. DOI:10.1161/ATV.0000000000000073
38. Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526-39. DOI:10.1093/eurheartj/ehy182
39. Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complains. J Am Coll Cardiol. 2017;70(10):290-301. DOI:10.1016/j.jacc.2017.07.752
40. Vell MS, Loomba R, Krishman A. Association of statin use with risk of liver disease, hepatocellular carcinoma and liver-related mortality. JAMA Network Open. 2023;6(6):e2320222. DOI:10.1001/jamanetworkopen.2023.20222
41. Warden BA, Guyton JR, Kovaks AS, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19-39. DOI:10.1016/j.jacl.2022.09.001
42. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al Aggressive LDL-C lowering and the brain: Impact on risk for dementia and hemorrhagic stroke: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43:e404-42. DOI:10.1161/ATV.0000000000000164
43. Sattar N. Statins and diabetes: What are the connections? Best Pract Res Clin Endocrinol Metab. 2023;37(3):101749. DOI:10.1016/j.beem.2023.101749
44. Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S47-57. DOI:10.1016/j.jacl.2014.02.011
45. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-34. DOI:10.1023/a:1005661516165
46. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412-22. DOI:10.1055/s-0029-1240010
47. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374-80. DOI:10.1016/j.jhep.2011.07.023
48. Kajinami K, Tsukamoto K, Koba S, et al. Statin Intolerance Clinical Guide 2018. J Atherosclerosis Thromb. 2020;27(4):375-96. DOI:10.5551/jat.50948
49. Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc Drugs Ther. 2021;35(4):841-52. DOI:10.1007/s10557-020-07139-x
50. Воевода М.И., Гуревич В.С., Ежов М.В., Сергиенко И.В. Инклисиран – новая эра в гиполипидемической терапии. Кардиология. 2022;62(6):57-62 [Voevoda MI, Gurevich VS, Ezhov MV, Sergienko IV. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia. 2022;62(6):57-62 (in Russian)]. DOI:10.18087/cardio.2022.6.n2115
51. Rosenson RS, Baker SK, Jacobson TA, et al.; The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S58-71. DOI:10.1016/j.jacl.2014.03.004
52. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-59. PMID:8245716
53. Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S5-16. DOI:10.1016/j.jacl.2014.02.013
54. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. 2012;5(6):746-55. DOI:10.1242/dmm.01012
55. de Boer AG, Gaillard PJ. Blood-brain barrier dysfunction and recovery. J Neural Transm (Vienna). 2006;113(4):455-62. DOI:10.1007/s00702-005-0375-4
56. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22). N Engl J Med. 2004;350(15):1495-504. DOI:10.1056/NEJMoa040583
57. Nicholls S, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87. DOI:10.1056/NEJMoa1110874
58. Nissen S, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13):1556-65. DOI:10.1001/jama.295.13.jpc60002
59. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-80. DOI:10.1016/j.amjcard.2006.10.022
60. Olmastroni E, Molari G, DeBeni N, et al. Statin use and risk of dementia or Alzheimer's disease: A systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804-14. DOI:10.1093/eurjpc/zwab208
61. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-58. DOI:10.1002/pds.3381
62. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. М., 2023 [Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. II Dedova, MV Shestakovoi, AIu Maiorova. 11-i vyp. Moscow, 2023 (in Russian)]. DOI:10.14341/DM13042
63. Цыганкова О.В., Евдокимова Н.Е., Байрамова С.С., Сусеков А.В. Статин-ассоциированный рабдомиолиз у женщины 60 лет с декомпенсированным сахарным диабетом 2 типа. Российский кардиологический журнал. 2021;26(11):44171 [Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: A case report. Russian Journal of Cardiology. 2021;26(11):4471 (in Russian)]. DOI:10.15829/1560-4071-2021-4471
64. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. DOI:10.1093/eurheartj/ehad192
65. Byrne RA, Rosselo X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. DOI:10.1093/eurheartj/ehad191
66. Davidson MH. Rosuvastatin safety: lessons from the FDA review and postapproval surveillance. Expert Opin Drug Safety. 2004;3(6):547-57. DOI:10.1517/14740338.3.6.547
67. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet. 2011;377(9784):2181-92. DOI:10.1016/S0140-6736(11)60739-3
68. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-94.e10. DOI:10.1016/j.ahj.2010.08.012
69. Sabouret P, Puymirat E, Kownator S, et al. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Panminerva Med. 2023;65(2):244-9. DOI:10.23736/S0031-0808.22.04777-2
70. Li JJ, Zhao SP, Zhao D, et al. 2023 China Guidelines for Lipid Management. J Geriatr Cardiology. 2023;20(9):621-63. DOI:10.26599/1671-5411.2023.09.008
71. Araujo F, Caldera D, Aguiar C, et al. Polypill use for the prevention of cardiovascular disease: A position paper. Rev Port Cardiol. 2023;42(10):861-72. DOI:10.1016/j.repc.2023.02.011
72. Puri R, Bansal M, Mehta V, et al. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV. J Clin Lipidology. 2024;18(3):e315-73. DOI:10.1016/j.jacl.2024.01.006
73. Bangalore S, Fayyad R, Kastelein JJ, et al. 2013 Cholesterol Guidelines Revisited: Percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis? Am J Med. 2016;129(4):384-91. DOI:10.1016/j.amjmed.2015.10.024
74. Метельская В.А., Шальнова С.А., Деев А.Д., и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016;1:15-23 [Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Russian Journal of Preventive Medicine. 2016;19(1):15-23 (in Russian)]. DOI:10.17116/profmed201619115-23
75. Мешков А.Н., Ершова А.И., Деев А.Д., и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012–2014 гг. Кардиоваскулярная терапия и профилактика. 2017;16(4):62-7 [Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: Results of the Esse-RF Study for the years 2012–2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7 (in Russian)]. DOI:10.15829/1728-8800-2017-4-62-67
76. Игонина Н.А., Журавлева Е.А., Кондрашева Е.А., и др. Анализ данных массового исследования холестерина у населения (к вопросу о референсных значениях холестерина). Клиническая лабораторная диагностика. 2013;1:11-7 [Igonina NA, Juravleva EA, Kondrasheva EA, et al. The analysis of data of large study of cholesterol level in population: On the issue of reference values of cholesterol). Russian Clinical Laboratory Diagnostics. 2013;1:11-7 (in Russian)].
77. Бойцов С.А., Шахнович Р.М., Терещенко С.Н., и др. Распространенность гиперлипидемии и особенности липидснижающей терапии у пациентов с инфарктом миокарда по данным Российского регистра острого инфаркта миокарда РЕГИОН-ИМ. Кардиология. 2022;62(7):12-22 [Boytsov SA, Shakhnovich RM, Tereschenko SN, et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12-22 (in Russian)]. DOI:10.18087/cardio.2022.7.n2051
78. Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С., и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I. Рациональная фармакотерапия в кардиологии. 2015;11(3):253-60 [Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I. Ration Pharmacother Cardiol. 2015;11(3):253-60 (in Russian)].
79. Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;11(4):70-8 [Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8 (in Russian)].
________________________________________________
2. Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG). ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. DOI:10.1016/j.atherosclerosis.2019.08.014
3. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab484
4. Narusheniia lipidnogo obmena. Klinicheskie rekomendatsii. 2023. Available at: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Accessed: 23.06.2024 (in Russian).
5. Ostryi koronarnyi sindrom bez pod"ema segmenta ST kardiogrammy. Klinicheskie rekomendatsii. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Accessed: 23.06.2024 (in Russian).
6. Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452 (in Russian). DOI:10.15829/1560-4071-2023-5452
7. Kotovskaya YV, Tkacheva ON, Sergienko IV. Lipid-lowering therapy for primary cardiovascular prevention in older adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119-32 (in Russian). DOI:10.18087/cardio.2020.6.n1037
8. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97. DOI:10.1056/NEJMoa1410489
9. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664
10. Schwartz GG, Steg GP, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-107. DOI:10.1056/NEJMoa1801174
11. Ray KK, Ference BA, Séverin T, et al. Word Heart Federation Cholesterol Roadmap 2022. Global Heart. 2022;17(1):75. DOI:10.5334/gh.1154
12. Romanelli RJ, Ito MK, Karalis DG, et al. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016. J Clin Lipidol. 2020;14(3):305-14. DOI:10.1016/j.jacl.2020.03.006
13. Navar AN, Kolkailah A, Gillard KK, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: A retrospective cohort study of 322153 patients. Circ Cardiovasc Qual Outcomes. 2023;16:e009787. DOI:10.1161/CIRCOUTCOMES.122.00978
14. Barrios V, Soronen L, Carter A et al. Lipid management across Europe in the real-world setting: A rapid evidence review. Cardiovascular Medicine. Curr Med Res Opin. 2021;37(12):2049-59. DOI:10.1080/03007995.2021.1973396
15. Ray K, Haq I, Manu MC; SANTORINI Study Investigators, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. DOI:10.1016/j.lanepe.2023.100624
16. Pinto L, Farghaly M, Nunna S, et al. Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates. PLoS One. 2022;17(9):e0268709. DOI:10.1371/journal.pone.0268709
17. Guo T, Chu C, Wang C, et al. Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: A sub analysis of Dyslipidemia International Study II – China. BMC Cardiovasc Disord. 2023;23(1):337. DOI:10.1186/s12872-023-03312-w
18. Susekov AV. Rationale for increasing doses of statins in everyday clinical practice. Kardiologiia. 2024;64(8):79-88 (in Russian). DOI:10.18087/cardio.2024.8.n2709
19. Drapkina OM, Imaeva AE, Kutsenko VA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791 (in Russian). DOI:10.15829/1728-8800-2023-3791
20. Papadaki A, Nolen-Doerr E, Mantzoros CS. The effect of the mediterranean diet on metabolic health: A systematic review and meta-analysis of controlled trials in adults. Nutrients. 2020;12(11):3342. DOI:10.3390/nu12113342
21. Susekov AV. Topical issues concerning modern lipid-lowering therapy. Consilium Medicum. 2022;24(1):20-7 (in Russian). DOI:10.26442/20751753.2022.1.201484
22. Susekov VA. Modern algorithms for statin therapy. Russian Journal of Cardiology. 2023;28(10):5594 (in Russian). DOI:10.15829/1560-4071-2023-5594
23. Brus S. Clinical evidence of the efficacy of Krka’s rosuvastatin in the treatment of hyperlipidemia with focus on additional doses. Krka Med Farm. 2014;26(38):62-71. DOI:10.15836/ccar.2014.320
24. European patent office. Munich. EP 2 387 566 B1. Available at: https://data.epo.org. Accessed: 17.10.2014.
25. Sergienko IV, Ansheles AA, Boytsov SA. Risk factors, lipid profile indicators and hypolipidemic therapy in patients of various categories of cardiovascular risk: the results of the Aterostop registry. Ateroskleroz i Dislipidemii = The Journal of Atherosclerosis and Dyslipidemias. 2023;2(51):43-53 (in Russian). DOI:10.34687/2219-8202.JAD.2023.02.0005
26. Rekomendatsii dlia vrachei po vedeniiu patsientov s dislipidemiei i aterosklerozom. Pod red. AV Susekova. Moscow: Re Media, 2022 (in Russian).
27. Ramaswami U, Humphries SE, Priestley-Barnham L, еt al. Current management of children and young people with heterozygous familial hypercholesterolaemia – HEART UK statement of care. Atherosclerosis. 2019;290:1-8. DOI:10.1016/j.atherosclerosis.2019.09.005
28. Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ. 2003;326:1407-8. Vasc Med. 2003;8(4):289-90. DOI:10.1191/1358863x03vm518xx
29. Orringer CE, Blaha MJ, Blankstein R, еt al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33-60. DOI:10.1016/j.jacl.2020.12.005
30. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement EAS consensus aortic stenosis. Eur Heart J. 2022;43(39):3925-46. DOI:10.1093/eurheartj/ehac361
31. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-93. DOI:10.1016/j.jacc.2021.06.011
32. Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): An update on a marker of residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94-102. DOI:10.1016/j.amjcard.2020.03.043
33. Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. DOI:10.1111/joim.13016
34. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis. 2018;275:265-72. DOI:10.1016/j.atherosclerosis.2018.06.814
35. Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, et al. Women, lipids, and atherosclerotic cardiovascular disease: A call to action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157-73. DOI:10.1093/eurheartj/ehad472
36. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-314. DOI:10.1016/j.kint.2023.10.018
37. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events a scientific statement from the AHA. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-81. DOI:10.1161/ATV.0000000000000073
38. Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526-39. DOI:10.1093/eurheartj/ehy182
39. Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complains. J Am Coll Cardiol. 2017;70(10):290-301. DOI:10.1016/j.jacc.2017.07.752
40. Vell MS, Loomba R, Krishman A. Association of statin use with risk of liver disease, hepatocellular carcinoma and liver-related mortality. JAMA Network Open. 2023;6(6):e2320222. DOI:10.1001/jamanetworkopen.2023.20222
41. Warden BA, Guyton JR, Kovaks AS, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19-39. DOI:10.1016/j.jacl.2022.09.001
42. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al Aggressive LDL-C lowering and the brain: Impact on risk for dementia and hemorrhagic stroke: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43:e404-42. DOI:10.1161/ATV.0000000000000164
43. Sattar N. Statins and diabetes: What are the connections? Best Pract Res Clin Endocrinol Metab. 2023;37(3):101749. DOI:10.1016/j.beem.2023.101749
44. Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S47-57. DOI:10.1016/j.jacl.2014.02.011
45. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-34. DOI:10.1023/a:1005661516165
46. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412-22. DOI:10.1055/s-0029-1240010
47. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374-80. DOI:10.1016/j.jhep.2011.07.023
48. Kajinami K, Tsukamoto K, Koba S, et al. Statin Intolerance Clinical Guide 2018. J Atherosclerosis Thromb. 2020;27(4):375-96. DOI:10.5551/jat.50948
49. Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc Drugs Ther. 2021;35(4):841-52. DOI:10.1007/s10557-020-07139-x
50. Voevoda MI, Gurevich VS, Ezhov MV, Sergienko IV. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia. 2022;62(6):57-62 (in Russian). DOI:10.18087/cardio.2022.6.n2115
51. Rosenson RS, Baker SK, Jacobson TA, et al.; The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S58-71. DOI:10.1016/j.jacl.2014.03.004
52. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-59. PMID:8245716
53. Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S5-16. DOI:10.1016/j.jacl.2014.02.013
54. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. 2012;5(6):746-55. DOI:10.1242/dmm.01012
55. de Boer AG, Gaillard PJ. Blood-brain barrier dysfunction and recovery. J Neural Transm (Vienna). 2006;113(4):455-62. DOI:10.1007/s00702-005-0375-4
56. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22). N Engl J Med. 2004;350(15):1495-504. DOI:10.1056/NEJMoa040583
57. Nicholls S, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87. DOI:10.1056/NEJMoa1110874
58. Nissen S, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13):1556-65. DOI:10.1001/jama.295.13.jpc60002
59. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-80. DOI:10.1016/j.amjcard.2006.10.022
60. Olmastroni E, Molari G, DeBeni N, et al. Statin use and risk of dementia or Alzheimer's disease: A systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804-14. DOI:10.1093/eurjpc/zwab208
61. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-58. DOI:10.1002/pds.3381
62. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. II Dedova, MV Shestakovoi, AIu Maiorova. 11-i vyp. Moscow, 2023 (in Russian). DOI:10.14341/DM13042
63. Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: A case report. Russian Journal of Cardiology. 2021;26(11):4471 (in Russian). DOI:10.15829/1560-4071-2021-4471
64. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. DOI:10.1093/eurheartj/ehad192
65. Byrne RA, Rosselo X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. DOI:10.1093/eurheartj/ehad191
66. Davidson MH. Rosuvastatin safety: lessons from the FDA review and postapproval surveillance. Expert Opin Drug Safety. 2004;3(6):547-57. DOI:10.1517/14740338.3.6.547
67. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet. 2011;377(9784):2181-92. DOI:10.1016/S0140-6736(11)60739-3
68. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-94.e10. DOI:10.1016/j.ahj.2010.08.012
69. Sabouret P, Puymirat E, Kownator S, et al. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Panminerva Med. 2023;65(2):244-9. DOI:10.23736/S0031-0808.22.04777-2
70. Li JJ, Zhao SP, Zhao D, et al. 2023 China Guidelines for Lipid Management. J Geriatr Cardiology. 2023;20(9):621-63. DOI:10.26599/1671-5411.2023.09.008
71. Araujo F, Caldera D, Aguiar C, et al. Polypill use for the prevention of cardiovascular disease: A position paper. Rev Port Cardiol. 2023;42(10):861-72. DOI:10.1016/j.repc.2023.02.011
72. Puri R, Bansal M, Mehta V, et al. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV. J Clin Lipidology. 2024;18(3):e315-73. DOI:10.1016/j.jacl.2024.01.006
73. Bangalore S, Fayyad R, Kastelein JJ, et al. 2013 Cholesterol Guidelines Revisited: Percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis? Am J Med. 2016;129(4):384-91. DOI:10.1016/j.amjmed.2015.10.024
74. Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Russian Journal of Preventive Medicine. 2016;19(1):15-23 (in Russian). DOI:10.17116/profmed201619115-23
75. Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: Results of the Esse-RF Study for the years 2012–2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7 (in Russian). DOI:10.15829/1728-8800-2017-4-62-67
76. Igonina NA, Juravleva EA, Kondrasheva EA, et al. The analysis of data of large study of cholesterol level in population: On the issue of reference values of cholesterol). Russian Clinical Laboratory Diagnostics. 2013;1:11-7 (in Russian).
77. Boytsov SA, Shakhnovich RM, Tereschenko SN, et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12-22 (in Russian). DOI:10.18087/cardio.2022.7.n2051
78. Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I. Ration Pharmacother Cardiol. 2015;11(3):253-60 (in Russian).
79. Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8 (in Russian).
Авторы
А.В. Сусеков*
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*asus99@mail.ru
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*asus99@mail.ru
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*asus99@mail.ru
________________________________________________
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*asus99@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.